The study represents a repurposing strategy, using dupilumab as a tool compound to probe whether immune-targeted therapy can address a biologically defined subgroup of MDD.
James Murrough, MD, PhD
Advertisement
Articles by James Murrough, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Veradermics Reports Sustained Hair Growth With VDPHL01 at 1 Year
2
PASI 100 Rates and Site-Specific Responses With Oral Psoriasis Therapies
3
Brepocitinib Clears Skin in 69% of Cutaneous Sarcoidosis Patients
4
Litifilimab Improves Cutaneous Lupus Symptoms Through 52 Weeks
5